Winsor Consult Group Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:N/A
Industry:Consulting
Founded:N/A
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Winsor Consult Group's estimated annual revenue is currently $6.2M per year.
  • Winsor Consult Group's estimated revenue per employee is $187,879

Employee Data

  • Winsor Consult Group has 33 Employees.
  • Winsor Consult Group grew their employee count by 32% last year.
  • Winsor Consult Group currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
N/A197N/AN/A-N/A
#2
$7.4M4631%N/A-N/A
#3
$22.4M1094%N/A-N/A
#4
$5.4M3535%N/A-N/A
#5
N/A8612%N/A-N/A
#6
$6.2M3332%N/A-N/A
#7
N/A1049%N/A-N/A
#8
N/A45N/AN/A-N/A
#9
N/A7N/AN/A-N/A
#10
$45.4M28422%N/A-N/A
Missing a competitor? Contribute!?
Submit

Winsor Consult Group specializes in assisting public agencies and public authorities to compile, organize and transform data contained in disparate systems into meaningful information. Winsor Consult Group provides management technology consulting services with a focus on giving your organization the ability to draw meaningful conclusions and take decisive actions based on your systems and data.

keywords:N/A

33

Number of Employees

$6.2M

Revenue (est)

1

Current Jobs

32%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Winsor Consult Group News

04/07/2019 - Tory leadership contest: Hunting and police pledges made

Campaign group the League Against Cruel Sports said Mr Hunt was "out ... But Sir Tom Winsor, Chief Inspector of Constabulary, said although ...

09/03/2019 - Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical ...

Patients in the vedolizumab group were administered vedolizumab IV 300 mg at .... Please consult with your local regulatory agency for approved labeling in your country. ... [11] Briskin M, Winsor-Hines D, Shyjan A, et al.

09/05/2019 - US Food & Drug Administration Accepts Takeda's Biologics ...

Furthermore, adverse event rates, including severe adverse events and infections, were similar between the SC and IV groups at week 52.